Sectors

ATRC
AtriCure, Inc.
48.35
2 x 27.83
2 x 49.70
bid
ask
-
0.19
0.39%
2 @ 04:10 PM
48.35 +0.00 (0.00%)
Ytd22.22%
1y30.71%
46.61
day range
48.84
25.36
52 week range
49.98
Open48.13Prev Close48.54Low46.61High48.84Mkt Cap2.46B
Vol529.12KAvg Vol886.70KEPS0.21P/E230.24Forward P/E111.98
Beta1.23Short Ratio4.52Inst. Own105.99%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning10-2750-d Avg37.83200-d Avg34.071yr Est49.56

ATRC News

benzinga.com
Piper Sandler Maintains Overweight on AtriCure, Raises Price Target to $60

Piper Sandler analyst Matt O'Brien maintains AtriCure (NASDAQ:ATRC) with a Overweight and rai

Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
zacks.com
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
businesswire.com
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday
benzinga.com
Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday

Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on

benzinga.com
BTIG Maintains Buy on AtriCure, Raises Price Target to $55

BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price targ

AtriCure: Promising Cardiovascular Surgical Platform
seekingalpha.com
AtriCure: Promising Cardiovascular Surgical Platform

AtriCure is building a broader surgical platform across appendage management, ablation, and postoper

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
marketbeat.com
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial

A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95
gurufocus.com
A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95

On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
fool.com
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduc

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
fool.com
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on Aug

A Look at AtriCure Inc (ATRC) After 6.0% Decline -- GF Value $39.32 vs Price $37.76
gurufocus.com
A Look at AtriCure Inc (ATRC) After 6.0% Decline -- GF Value $39.32 vs Price $37.76

On July 31, 2026, AtriCure Inc (ATRC) shares fell 6.0% today, bringing the current price to $37.76.

Top 3 Health Care Stocks That May Implode This Month
benzinga.com
Top 3 Health Care Stocks That May Implode This Month

RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high

benzinga.com
UBS Maintains Buy on AtriCure, Lowers Price Target to $50

UBS analyst Priya Sachdeva maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price targe

AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript
seekingalpha.com
AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript

AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript

AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
zacks.com
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the q

AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates
zacks.com
AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates

AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Est

AtriCure Q2 Earnings Call Highlights
marketbeat.com
AtriCure Q2 Earnings Call Highlights

AtriCure NASDAQ: ATRC reported double-digit revenue growth and a return to GAAP profitability in the

AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript
benzinga.com
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript

AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from th

benzinga.com
AtriCure Q2 Adj. EPS $0.18 Beats $0.00 Estimate, Sales $153.600M Beat $151.842M Estimate

AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.18 per share which beat the analyst consens

benzinga.com
AtriCure Raises FY2026 Adj EPS Guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 Est; Raises FY2026

AtriCure (NASDAQ:ATRC) raises FY2026 Adj EPS guidance from $0.00-$0.04 to $0.24-$0.32 vs $0.06 analy

AtriCure Reports Second Quarter 2026 Financial Results
businesswire.com
AtriCure Reports Second Quarter 2026 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

Earnings Scheduled For July 23, 2026
benzinga.com
Earnings Scheduled For July 23, 2026

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quar

AtriCure to Announce Second Quarter 2026 Financial Results
gurufocus.com
AtriCure to Announce Second Quarter 2026 Financial Results

[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments

AtriCure to Announce Second Quarter 2026 Financial Results
businesswire.com
AtriCure to Announce Second Quarter 2026 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
zacks.com
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?

AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The la

Do Options Traders Know Something About AtriCure Stock We Don't?
zacks.com
Do Options Traders Know Something About AtriCure Stock We Don't?

Investors need to pay close attention to ATRC stock based on the movements in the options market lat

AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc

AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc

AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
gurufocus.com
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference

[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments

AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
businesswire.com
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatme

benzinga.com
Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $55

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises

AtriCure Q1 2026 Earnings Call Transcript
benzinga.com
AtriCure Q1 2026 Earnings Call Transcript

benzinga.com
AtriCure Lowers FY2026 Adj EPS Guidance from $0.09-$0.15 to $0.00-$0.04 vs $0.07 Est; Affirms FY2026

2026 Financial GuidanceFull year 2026 revenue is projected to be approximately $600 million to $610

benzinga.com
AtriCure Q1 Adj. EPS $0.00 Beats $(0.06) Estimate, Sales $141.249M Beat $139.812M Estimate

AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.00 per share which beat the analyst consens

Earnings Scheduled For May 5, 2026
benzinga.com
Earnings Scheduled For May 5, 2026

Demystifying AtriCure: Insights From 6 Analyst Reviews
benzinga.com
Demystifying AtriCure: Insights From 6 Analyst Reviews

benzinga.com
Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $53

Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers

benzinga.com
UBS Maintains Buy on AtriCure, Lowers Price Target to $55

UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price ta

This Masimo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
benzinga.com
This Masimo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

benzinga.com
Citizens Maintains Market Outperform on AtriCure, Lowers Price Target to $52

Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and low

benzinga.com
Update: AtriCure Sees FY2026 Adj EPS $0.09-$0.15 vs $(0.04) Est; Affirms FY2026 Sales Guidance of $6

AtriCure (NASDAQ:ATRC) is looking for FY2026 Adj EPS of $0.09-$0.15 vs $(0.04) analyst estimate. Aff

benzinga.com
AtriCure Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $602.104M Est

AtriCure (NASDAQ:ATRC) affirms FY2026 sales outlook from $600.000 million-$610.000 million to $600.0

AtriCure Q4 Earnings Summary & Key Takeaways
benzinga.com
AtriCure Q4 Earnings Summary & Key Takeaways

benzinga.com
AtriCure Q4 Adj. EPS $0.06 Beats $(0.10) Estimate, Sales $140.500M Beat $139.777M Estimate

AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.06 per share which beat the analyst consens

Earnings Scheduled For February 17, 2026
benzinga.com
Earnings Scheduled For February 17, 2026

Insights into AtriCure's Upcoming Earnings
benzinga.com
Insights into AtriCure's Upcoming Earnings

benzinga.com
AtriCure Sees FY26 Revenue Guidance Of $600M-$610M, Adjusted EBITDA $80M-$82M

2026 Financial GuidanceManagement projects 2026 revenue of approximately $600 million to $610 millio

benzinga.com
AtriCure Reports Preliminary Q4 2025 Revenue Of $140.5M; FY25 Revenue Of $534.5M; Projects Positive

AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fi

benzinga.com
JP Morgan Maintains Overweight on AtriCure, Raises Price Target to $48

JP Morgan analyst Lilia-Celine Lozada maintains AtriCure (NASDAQ:ATRC) with a Overweight and rais

Earnings Scheduled For October 29, 2025
benzinga.com
Earnings Scheduled For October 29, 2025

Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket